ORPHA:319325
Tubulocystic renal cell carcinoma
Publications
568
86.2th percentile
Trials
1
Interventional, condition-specific
Researchers
1,092
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Tubulocystic renal cell carcinoma is an extremely rare subtype of renal cell carcinoma most frequently characterized by a small, solitary, well-circumscribed, unencapsulated renal tumor composed of multiple small to medium-sized cysts with a white or gray, spongy ("bubble wrap-like") cut surface. Patients are usually asymptomatic or could manifest with abdominal pain, abdominal distension and/or hematuria. Progression, recurrence and metastasis rarely occur although lymph node, bone, pleura and liver metastases have been reported.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017890
- UMLS:C4288091
- NCIT:C126303
Additional Mondo synonyms (1)
Tubulocystic renal cell cancer
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
568 matched papers (336 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
568
568 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
568 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
336 in the last 10 years · high confidence · 86.2th percentile (publications denominator)
Phrase hits: 568 · MeSH hits: 0
Who's working on it?
1,092
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hes O8 papers · 2023
Department of Pathology, Charles University in Prague, Faculty of Medicine and University Hospital in Plzen, Plzen, Czech Republic.
Papers in Europe PMC - 02Wang Y7 papers · 2026
Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, No.58 Zhongshan Road 2, Guangzhou, 510080, People's Republic of China. wyan29@mail.sysu.edu.cn.
Papers in Europe PMC - 03Zhang Y7 papers · 2026
Department of Radiology, Ningbo Medical Center LiHuiLi Hospital, 1111 Jiangnan road, Ningbo, 315040, Zhejiang, People's Republic of China. zyqa666888@163.com.
Papers in Europe PMC - 04Li Y6 papers · 2026
Department of Neurosurgery, Shaanxi Provincial People's Hospital, Xi'an, China.
Papers in Europe PMC - 05Liu Y6 papers · 2025
Department of Pathology, Wannan Medical College First Affiliated Hospital, Yijishan Hospital, Wuhu, Anhui, China.
Papers in Europe PMC - 06Trpkov K6 papers · 2026
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. kiril.trpkov@albertaprecisionlabs.ca.
Papers in Europe PMC - 07Xu Y6 papers · 2025
Department of Pathology, Guiqian International General Hospital, Guiyang City, Guizhou Province, China.
Papers in Europe PMC - 08Li L5 papers · 2025
Department of Cardiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.
Papers in Europe PMC - 09Mehra R5 papers · 2026
Department of Pathology and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Papers in Europe PMC - 10Wang Z5 papers · 2025
Department of Radiology, Zhongxiang People's Hospital, No. 19, Xiangyun Avenue, Zhongxiang, 431900, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 1,168 trials are registered for renal cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
high confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: renal cell carcinoma
1,168
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05023265·RECRUITING·Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Conditions: Renal Cell Carcinoma·Matched via name phrase
- NCT07369505·RECRUITING·Sapu003 in Advanced mTOR-sensitive Solid Tumors
Conditions: Breast Cancer Metastatic · Renal Cell Carcinoma (RCC) · Neuroendocrine Tumors · Tuberous Sclerosis Complex (TSC)·Matched via name phrase
- NCT07179770·RECRUITING·Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
Conditions: Metastatic Clear Cell Renal Cell Carcinoma·Matched via name phrase
- NCT06783348·RECRUITING·Radiopharmaceutical Treatment of Advanced Kidney Cancer
Conditions: Metastatic Clear Cell Renal Cell Carcinoma·Matched via name phrase
- NCT05269381·RECRUITING·Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Conditions: Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIB Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8·Matched via name phrase
- NCT05155033·RECRUITING·Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Conditions: Metastatic Melanoma · Advanced Locoregional Melanoma · Metastatic Renal Cell Carcinoma · Clear Cell Histology·Matched via name phrase
- NCT07218692·NOT YET RECRUITING·RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Conditions: Advanced Clear Cell Renal Cell Carcinoma · Advanced Renal Cell Carcinoma · Advanced Sarcomatoid Renal Cell Carcinoma · Metastatic Clear Cell Renal Cell Carcinoma·Matched via name phrase
- NCT07128680·RECRUITING·Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Conditions: Advanced Clear Cell Renal Cell Carcinoma · Advanced Sarcomatoid Renal Cell Carcinoma · Metastatic Clear Cell Renal Cell Carcinoma · Metastatic Sarcomatoid Renal Cell Carcinoma·Matched via name phrase
- NCT06976021·NOT YET RECRUITING·Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Conditions: Triple Negative Breast Cancer · Uterine Cervical Cancer · Uterine Corpus Cancer · Malignant Melanoma·Matched via name phrase
- NCT04693377·RECRUITING·Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Conditions: Castration-Resistant Prostate Carcinoma · Metastatic Colorectal Carcinoma · Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Solid Neoplasm·Matched via name phrase
- NCT06642220·RECRUITING·Ablative Radioembolization of Renal Cell Carcinoma Trial
Conditions: Renal Cell Carcinoma (RCC) · Radioembolization·Matched via name phrase
- NCT07219576·RECRUITING·Retifanlimab and Ruxolitinib In Solid Malignancies
Conditions: Non Small Cell Lung Carcinoma · Renal Cell Carcinoma·Matched via name phrase
- NCT06053658·RECRUITING·Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma·Matched via name phrase
- NCT07620574·NOT YET RECRUITING·Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Conditions: Cancer · Renal Cell Carcinoma (RCC) · Pancreatic Neuroendocrine Tumors (pNET) · Extra-Pancreatic NET (epNET)·Matched via name phrase
- NCT04299646·RECRUITING·A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Conditions: Metastatic Renal Cell Carcinoma · Radiotherapy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Tubulocystic renal cell carcinoma" OR "Tubulocystic renal cell cancer"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Tubulocystic renal cell carcinoma" OR "Tubulocystic renal cell cancer"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"renal cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:26:36.969Z
